Key terms

About AMRN

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AMRN news

Yesterday 11:21am ET Biotech Alert: Searches spiking for these stocks today May 01 10:25am ET Amarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European Growth May 01 7:02am ET Amarin reports Q1 EPS (1c), consensus (3c) Apr 22 1:12pm ET Amarin Shareholders Show Strong Support at Annual Meeting Apr 22 8:17am ET Amarin anounces results of annual general meeting of shareholders Apr 08 8:31am ET Amarin highlights key data on mechanistic insights into eicosapentaenoic acid Apr 07 6:48am ET Amarin presents new REDUCE-IT analyses at ACC.24 Apr 03 8:14am ET Amarin extends Vazkepa commercial runway in Europe for eight more years Mar 25 8:23am ET Amarin to present research on benefits of VASCEPA/VAZKEPA Mar 08 8:45am ET Largest borrow rate increases among liquid names Mar 05 8:45am ET Largest borrow rate increases among liquid names Mar 01 1:00am ET Amarin Corporation Plc’s New Competition Risk – A Cause for Worry? Feb 29 12:35pm ET Amarin’s Sell Rating Affirmed Amid Declining U.S. Sales and Uncertain International Expansion Feb 29 7:06am ET Amarin reports Q4 EPS 0c, consensus (3c) Feb 29 7:05am ET Options Volatility and Implied Earnings Moves Today, February 29, 2024 Feb 20 8:45am ET Largest borrow rate increases among liquid names Feb 14 8:45am ET Largest borrow rate increases among liquid names

No recent press releases are available for AMRN

AMRN Financials

1-year income & revenue

Key terms

AMRN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AMRN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms